Research Activity – Page 41

Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years

10 months ago talkbio0Tagged Capacity, development aspects, Drug Industry, Investments, Italy, Johnson and Johnson, Manufacture, research, Upgrade

Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry

Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment

10 months ago talkbio0Tagged Antipsychotic Agents, Caplyta, Intra-Cellular Therapies, Lumateperone, Mental Depression, Phase 3 Clinical Trials

Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment

FDA Places Partial Clinical Hold on Zentalis’ Azenosertib Cancer Studies Following Two Sepsis Deaths

10 months ago talkbio0Tagged cancer studies, Cessation of life, Clinical Trials, Inhibitor, Partial, patient safety, Septicemia, Study on Hold, United States Food and Drug Administration, WEE1 gene, Zentalis

Zentalis Pharmaceuticals, azenosertib, FDA, partial clinical hold, cancer studies, sepsis deaths, WEE1 inhibitor, clinical trials, patient safety

AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial

10 months ago talkbio0Tagged AKT1 protein, human, AstraZeneca, CAPItello-290, capivasertib, Overall Survival, paclitaxel, Phase 3 Clinical Trials, PIK3CA gene, PTEN gene, Triple Negative Breast Neoplasms, Truqap

AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN

Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar

10 months ago talkbio0Tagged AbbVie, adjunctive therapy, Antipsychotic Agents, Approved, Caplyta, Clinical Trials, Depressive disorder, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, United States Food and Drug Administration, Vraylar

Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

11 months ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results

11 months ago talkbio0Tagged Autoimmune Diseases, FCGRT gene, Inhibitor, Johnson & Johnson, Nipocalimab, Phase 2 Clinical Trials, Sjögren 's disease

nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor

Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients

11 months ago talkbio0Tagged Clinical Trials, concerns, Gilead, magrolimab, Malignant Neoplasms, Miller Dieker syndrome, MYELODYSPLASTIC SYNDROME, Safety

Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns

Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients

11 months ago talkbio0Tagged Clinical Research, Enhance (action), Gilead, Hematologic Neoplasms, Increased, magrolimab, Risk of Death

Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study

Revolutionizing Clinical Trials: Leveraging AI for Enhanced Efficiency and Accuracy

11 months ago talkbio0Tagged Accurate (qualifier), AI-Powered Tools, Artificial Intelligence, Auditory recruitment, Clinical Trials, Data Analysis, Efficiency, Precision Medicine

Artificial Intelligence, Clinical Trials, Data Analysis, Patient Recruitment, Personalized Medicine, AI-Powered Tools, Medical Research, Efficiency, Accuracy